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ABSTRACT
Objectives To assess the degree of frailty in older people 
with different advanced diseases and its relationship with 
end- of- life illness trajectories and survival.
Methods Prospective, observational study, including 
all patients admitted to the Acute Geriatric Unit of the 
University Hospital of Vic (Spain) during 12 consecutive 
months (2014–2015), followed for up to 2 years. 
Participants were identified as end- of- life people (EOLp) 
using the NECPAL (NECesidades PALiativas, palliative care 
needs) tool and were classified according to their dominant 
illness trajectory. The Frail- VIG index (Valoración Integral 
Geriátrica, Comprehensive Geriatric Assessment) was 
used to quantify frailty degree, to calculate the relationship 
between frailty and mortality (Receiver Operating 
Characteristic (ROC) curves), and to assess the combined 
effect of frailty degree and illness trajectories on survival 
(Cox proportional hazards model). Survival curves were 
plotted using the Kaplan- Meier estimator with participants 
classified into four groups (ie, no frailty, mild frailty, 
moderate frailty and advanced frailty) and were compared 
using the log- rank test.
Results Of the 590 persons with a mean (SD) age of 86.4 
(5.6) years recruited, 260 (44.1%) were identified as EOLp, 
distributed into cancer (n=31, 11.9%), organ failure (n=79, 
30.4%), dementia (n=86, 33.1%) and multimorbidity 
(n=64, 24.6%) trajectories. All 260 EOLp had some 
degree of frailty, mostly advanced frailty (n=184, 70.8%), 
regardless of the illness trajectory, and 220 (84.6%) died 
within 2 years. The area under the ROC curve (95% CI) 
after 2 years of follow- up for EOLp was 0.87 (0.84 to 0.92) 
with different patterns of survival decline in the different 
end- of- life trajectories (p<0.0001). Cox regression 
analyses showed that each additional deficit of the Frail- 
VIG index increased the risk of death by 61.5%, 30.1%, 
29.6% and 12.9% in people with dementia, organ failure, 
multimorbidity and cancer, respectively (p<0.01 for all the 
coefficients).
Conclusions All older people towards the end- of- life 
in this study were frail, mostly with advanced frailty. 
The degree of frailty is related to survival across the 
different illness trajectories despite the differing survival 
patterns among trajectories. Frailty indexes may be useful 
to assess end- of- life older people, regardless of their 
trajectory.
INTRODUCTION
The model of care for patients with advanced 
chronic conditions is currently shifting 
towards a new paradigm, characterised by 
early identification of persons with any disease 
or chronic condition who would benefit 
from palliative care1 2—this corresponds to 
the first transition in palliative care. Despite 
the benefits of this early identification,3 the 
increasing number of people with palliative 
care needs, together with their high hetero-
geneity regarding age, needs, diseases and 
chronic illnesses, poses novel challenges for 
early identification and assessment of these 
patients.4 5 Indeed, the progression towards 
the end of life is conditioned by multiple vari-
ables and is strictly individual: not all people 
Strengths and limitations of this study
 ► To our knowledge, this is the first study that evaluat-
ed the degree of frailty using a frailty index in older 
patients with different advanced illness trajectories.
 ► This is a real- life study, using tools routinely applied 
in the Acute Geriatric Unit conducting this study, the 
NECPAL, to identify people with palliative care needs, 
and the Frail- VIG index, to measure the degree of 
frailty and personalisation of the interventions.
 ► In this context, assessing frailty degree may con-
tribute to establish a common language between 
geriatric and palliative knowledge, with the goal of 
providing a better care for older people with pallia-
tive care needs, specially those in the first end- of- 
life transition.
 ► The use of a single computer system collecting the 
mortality status reported by all health providers pre-
vented loss of patients and missing data, increasing 
the accuracy of the results.
 ► The results from this study were obtained in a very 
old population and the Frail- VIG index lacks suffi-
cient external validation, potentially limiting their 
generalisability and raising the need for further stud-
ies in younger populations.
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age in the same way nor reach the final situation with the 
same circumstances or needs.6
In the context of this new paradigm of ‘early palliative 
care’, some authors have pointed to frailty as a crucial 
concept for persons needing palliative care―particularly 
older people with multimorbidity―their caregivers and 
healthcare professionals, to learn to manage the uncer-
tainty and complexity of these end- of- life situations.7–9 
Given the relationship between mortality and frailty,10 the 
concept of frailty has been proposed as a criterion useful 
in the three key steps ensuring good palliative care,5 6 11 12 
including (1) early identification of persons in end- of- life 
situation (particularly in cases of advanced frailty); (2) 
multidimensional assessment and situational diagnosis; 
and (3) drafting an advanced care plan and sharing 
decision- making.
Regardless of the proposed uses of frailty as an indi-
cator, palliative care and geriatrics have traditionally used 
this concept, although with different perspectives.8 In 
the setting of palliative care, frailty has equated to the 
third end- of- life trajectory and defined as the gradual 
decline in physical function, typically associated with 
dementia.13 14 In contrast, from the geriatric perspective, 
frailty is rather a multidimensional clinical entity defined 
as a vulnerability state against stressing factors due to 
limited compensatory mechanisms.15 Of the multiple 
instruments developed to assess frailty, frailty indexes (ie, 
the ratio between accumulated deficits in a given person 
and the total possible deficits) may have utility in iden-
tifying people with frailty for end- of- life care across all 
disease groups.8 16
A better understanding of how to provide the best 
palliative care for frail older people has become an inter-
national priority17 and, considering the increased diffi-
culty of identifying dying people in very old age (>85 
years),18–20 the concept of frailty is increasingly acknowl-
edged as a cornerstone in the assessment and care of 
persons in an end- of- life situation and needing palliative 
care.15 21 However, a consensus on how to use the concept 
of frailty to provide palliative care to end- of- life people 
(EOLp) remains to be established.15 22 23 In this study, 
aimed at improving the care of end- of- life older people, 
we assessed the degree of frailty in a geriatric cohort with 
different advanced diseases and its relationship with end- 
of- life illness trajectories and survival.
METHODS
Study design and participants
This was a prospective, observational study, including all 
patients admitted to the Acute Geriatric Unit (AGU) at 
the University Hospital of Vic (Barcelona, Spain) during 
12 consecutive months (January 2014–January 2015). The 
University Hospital of Vic is a 200- bed acute care hospital 
covering a population area of 156 000 inhabitants. Admis-
sion criteria to the AGU, which were the criteria for inclu-
sion in this study, were age ≥85 years, cognitive decline 
and/or end- of- life situation; no exclusion criteria were 
defined. The methods, including study design, variables, 
data sources and study size, have been described in a 
previous study.24 Of the patients included in this study (ie, 
those admitted to the AGU), those identified as non- end- 
of- life were included in a control group of patients aged 
≥85 years and/or with cognitive decline. The results of 
this subanalysis are reported according to the Strength-
ening the Reporting of Observational Studies in Epide-
miology (STROBE) recommendations.25 All patients and 
family relatives of patients with advanced dementia situ-
ation (Global Deterioration Scale (GDS)≥6) signed the 
written informed consent for participation before any 
data were recorded.
Patient and public involvement
This research was done without patient involvement. 
Patients were not invited to comment on the study 
design and were not consulted to develop patient rele-
vant outcomes or interpret the results. Patients were not 
invited to contribute to the writing or editing of this docu-
ment for readability or accuracy.
Variables and data sources
Frailty was assessed using the Frail- VIG index, a tool 
consisting of 22 questions to assess 25 deficits commonly 
associated with age and adverse health outcomes, based 
on the cumulative deficit model of frailty. Fifteen of the 22 
questions refer to chronic conditions, including geriatric 
conditions and syndromes. The Frail- VIG index (‘VIG’ 
is the Spanish/Catalan abbreviation for CGA (Compre-
hensive Geriatric Assessment)) is a continuous variable 
expressed as a score ranging from 0 to 1. To simplify the 
representation of the survival curves, Frail- VIG index 
scores were expressed as a categorical variable classified 
into four groups according to the degree of frailty: no 
frailty (Frail- VIG index score <0.2), mild frailty (Frail- VIG 
index score 0.2–0.35), moderate frailty (Frail- VIG index 
score 0.36–0.5) and advanced frailty (Frail- VIG index 
score >0.5). In addition to its predictive value, previous 
studies have shown the content, construct, criteria and 
convergent- divergent construct validity of the Frail- VIG 
index.24 26–28 EOLp were identified using the NECPAL 
(NECesidades PALiativas, palliative care needs) tool, a 
validated tool for the early identification of the need for 
palliative care among individuals with limited life expec-
tancy.29–31 EOLp were classified into the three arche-
typal end- of- life trajectories according to the severity 
and/or progression criteria for their main underlying 
disease: cancer, organ failure (including chronic pulmo-
nary disease, chronic heart disease, serious chronic liver 
disease and serious chronic renal disease) and dementia 
(including other chronic neurological diseases). People 
with palliative care needs without a predominant 
advanced disease were identified as ‘multimorbidity’ 
group or trajectory, since all had two or more underlying 
chronic conditions.
After inclusion of the last patient in the study (ie, last 
admitted patient in the AGU before 15 January 2015) and 
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before starting data analysis in 2017, patients were followed 
for up to 24 months (2015–beginning 2017). Information 
regarding the patient status after the 24- month follow- up 
period was obtained from the Shared Medical Record in 
Catalonia (HC3), a sole electronic database accessible to 
all healthcare providers in Catalonia that allows health-
care professionals to reliably determine whether a patient 
is ‘active’ (alive) or deceased (including date of death).32
Statistical analysis
Qualitative variables were presented as frequencies 
and percentages, whereas quantitative variables were 
presented as the mean and SD. Qualitative variables were 
compared using the Pearson’s χ2 test. In the complete 
cohort, the concordance between Frail- VIG index score 
and survival was evaluated using the C- statistics, and 
the Kaplan- Meier estimator was used to plot survival 
curves for the four frailty degree subgroups, which were 
compared using the log- rank test. In the group of people 
identified as end- of- life, survival curves for each illness 
trajectory were plotted using the Kaplan- Meier esti-
mator and were compared using the log- rank test. A Cox 
proportional hazards model with the interaction between 
Frail- VIG index score and illness trajectories was calcu-
lated. Details of the construction of the Cox proportional 
hazards model and calculation of the HRs are provided in 
the online supplemental material file. The assumption of 
proportional hazards was checked using the Schoenfeld 
residuals and a goodness- of- fit test.
The Receiver Operating Characteristic (ROC) curves 
were used to assess the ability of the Frail- VIG index 
to predict survival at 1 and 2 years by measuring their 
area under the receiver- operating curve (AUC) for the 
different illness trajectories. The significance level for 
all analyses was set at a two- sided α=0.05. The descriptive 
statistics analysis of the variables was performed using the 
SPSS software program version 24 (IBM), and the survival 
analysis was performed using the survival and pROC pack-
ages from the R project (https://www. r- project. org).
RESULTS
Patient characteristics and end-of-life status
The study included 590 patients with a mean (SD, range) 
age of 86.4 (5.6, 48–105) years, of whom 339 (57.5%) 
were female. Based on the Frail- VIG index scores, 543 
(92%) patients showed some degree of frailty, with 111 
(18.8%), 207 (35.1%) and 225 (38.1%) patients showing 
mild, moderate and advanced frailty, respectively. Of the 
590 patients included, 53 (8.9%) died during hospitalisa-
tion, and 330 (55.9%) and 260 (44.1%) were identified 
as non- EOLp and EOLp, respectively. Of the 260 EOLp, 
31 (11.9%), 79 (30.4%), 86 (33.1%) and 64 (24.6%) were 
classified in cancer, organ failure, dementia and multi-
morbidity illness trajectories, respectively.
Relationship between end-of-life status and patient 
characteristics
EOLp and non- EOLp had similar mean age and sex 
frequencies, but differed in the distribution among the 
four frailty groups: all EOLp (260) and 283 (85.8%) of 
the 330 non- EOLp were frail to some extent, with 252 
(96.9%) and 180 (54.5%) showing moderate or advanced 
frailty in the EOLp and non- EOLp groups, respectively. 
Table 1 summarises the frequencies of EOLp and non- 
EOLp across the various frailty categories and their main 
demographic characteristics.
Correspondingly, median Frail- VIG index scores were 
significantly higher in EOLp compared with non- EOLp: 
0.56 and 0.36, respectively (p<0.001). In EOLp, the 
predominant frailty degree was persistently advanced 
for all end- of- life trajectory categories: cancer, organ 
failure, dementia and multimorbidity (range 68%–75%) 
(table 2). All EOLp in the multimorbidity trajectory 
(n=64) were classified in the moderate and advanced 
frailty groups.
Relationship between frailty degree and survival
Of the complete cohort (EOLp and non- EOLp), 338 
(57.3%) study patients died during the 2- year follow- up 
period. Mortality was significantly higher in EOLp than 
in non- EOLp: 220 (84.6%) and 118 (35.7%), respec-
tively (p<0.001). The log- rank test comparing the survival 
curves of each frailty degree revealed significant differ-
ences in the overall population (χ2=423, p<0.0001), EOLp 
(χ2=69.9, p<0.0001) and non- EOLp (χ2=122, p<0.0001) 
(figure 1). Correspondingly, the C coefficient for concor-
dance between the survival time and the Frail- VIG score 
was 0.8, indicating that higher scores of the Frail- VIG 
index are associated with lower survival.
Relationship between frailty degree and survival in EOLp
The frequencies of death at the end of the 2- year follow- up 
period for each trajectory in EOLp are presented in 
Table 1 Classification of study patients according to the Frail- VIG index scores, demographic characteristics and end- of- life 
status (N=590)
Demographic characteristics Frailty degree, n (%)
Age (years), mean (SD) Sex (% of women) Not frail Mild frailty Moderate frailty Advanced frailty
EOLp 86.3 (5.8) 54.6 0 (0) 8 (3.1) 68 (26.1) 184 (70.8)
Non- EOLp 86.5 (5.4) 59.7 47 (14.3) 103 (31.2) 139 (42.1) 41 (12.4)
EOLp, end- of- life people; non- EOLp, non- end- of- life people.
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table 3. Survival curves, plotted using the Kaplan- Meier 
model for each frailty category (ie, mild, intermediate 
and advanced), differed among the different end- of- 
life trajectories, revealing different patterns of survival 
decline according to the frailty degree (figure 2).
A Cox regression model with the interaction between 
Frail- VIG index and illness trajectories revealed that the 
effect of the frailty degree on survival was associated 
with illness trajectories (p<0.01 for all the coefficients), 
even though the influence of illness trajectory progres-
sively decreased as the frailty degree increased (Figure 3 
and online supplemental table S1). Sex and age were 
excluded as covariates due to their lack of statistical 
significance (online supplemental table S2 and S3). The 
proportional hazard assumption was supported by the 
Schoenfeld residuals (p>0.1 for both global and each 
covariate tests). The estimated HRs were 1.61 for people 
with dementia (95% CI 1.43 to 1.81), 1.30 for people 
with organ failure (95% CI 1.18 to 1.43), 1.30 for people 
with multimorbidity (95% CI 1.18 to 1.42) and 1.13 for 
people with cancer (95% CI 1.02 to 1.25) (online supple-
mental table S4 and S5). These results show that for each 
additional deficit of the total of 25 deficits assessed (ie, 
a 0.04 increase in the Frail- VIG index), the risk of death 
increased by 61.5%, 30.1%, 29.6% and 12.9% in people 
with dementia, organ failure, multimorbidity and cancer, 
respectively.
The ROC analysis of the Frail- VIG index for the EOLp 
showed an AUC of 0.87 (95% CI 0.83 to 0.92) after 1 year 
and 0.87 (95% CI 0.84 to 0.92) after 2 years of follow- up. 
Of the 184 EOLp with advanced frailty (Frail- VIG index 
score >0.5), 178 (96.7%) had died at 2 years of follow- up. 
The AUC differed among each of the four end- of- life 
trajectories: cancer (1 and 0.93), organ failure (0.86 and 
0.90), dementia (0.92 and 0.92) and multimorbidity (0.91 
and 0.94), after 1 and 2 years of follow- up, respectively. 
Despite these differences, the AUC remained high irre-
spective of the illness trajectory. Regarding the sensitivity 
and specificity of the Frail- VIG index as prognosis factor 
of mortality, the most sensitive and specific cut- off was 
0.5 at both 1 and 2 years after follow- up, showing a sensi-
tivity of 0.81 and 0.85 and a specificity of 0.83 and 0.81, 
respectively.
Table 2 Classification of end- of- life people according to demographic characteristics, Frail- VIG index scores and end- of- life 
trajectory (n=260), n (%)
Demographic characteristics Frailty degree, n (%)
Age (years), 
mean (SD)
Sex (% of 





Cancer 85.7 (5.4) 45.2 0 (0) 3 (9.7) 7 (22.6) 21 (67.7) 31 (11.9)
Organ failure 86.9 (5.3) 46.8 0 (0) 4 (5.1) 20 (25.3) 55 (69.6) 79 (30.4)
Dementia 85.4 (5.3) 65.1 0 (0) 1 (1.1) 25 (29.1) 60 (69.8) 86 (33.1)
Multimorbidity 86.9 (7.3) 54.7 0 (0) 0 (0) 16 (25.0) 48 (75.0) 64 (24.6)
Total 86.3 (5.8) 54.6 0 (0) 8 (3.1) 68 (26.1) 184 (70.8) 260
Figure 1 Survival according to the degree of frailty in (A) the total study patients, (B) end- of- life people and (C) non- end- of- life 
people.
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DISCUSSION
In this prospective, observational study including 590 
patients admitted at an AGU, we found that all older 
patients were frail towards the end of life (the prevalence 
of moderate- to- advanced frailty was 97% among people 
within an end- of- life trajectory and 55% outside it). 
Furthermore, advanced frailty was the predominant frailty 
category (ranged 68%–75%) for all end- of- life trajecto-
ries: cancer, organ failure, dementia and multimorbidity. 
Overall, the Frail- VIG index had a high capacity to predict 
death at 1 and 2 years (AUC 0.87), although to a different 
extent for the end- of- life categories cancer, organ failure, 
dementia and multimorbidity (AUC was always >0.86 for 
mortality at either 1 or 2 years). This finding confirms the 
hypothesis that the degree of frailty is related to prognosis 
regardless of the illness trajectory.
The characteristics and outcomes of the cohort assessed 
in this study, which included all patients admitted to an 
AGU, were similar to those previously reported. All the 
persons assessed in this study had a Frail- VIG index score 
Table 3 Status of end- of- life people according to the Frail- VIG index scores and end- of- life trajectory after the 2- year follow- 
up (n=260), n (%)
N Status Mild frailty Moderate frailty Advanced frailty Total
Cancer 31 Dead 2 (6.5) 7 (22.6) 21 (67.7) 30 (96.8)
Alive 1 (3.2) 0 (0) 0 (0) 1 (3.2)
Organ failure 79 Dead 2 (2.5) 16 (20.2) 54 (68.4) 72 (91.1)
Alive 2 (2.5) 4 (5.1) 1 (1.3) 7 (8.9)
Dementia 86 Dead 1 (1.2) 6 (6.9) 55 (64.0) 62 (72.1)
Alive 0 (0) 19 (22.1) 5 (5.8) 24 (27.9)
Multimorbidity 64 Dead 0 (0) 8 (12.5) 48 (75.0) 56 (87.5)
Alive 0 (0) 8 (12.5) 0 (0) 8 (12.5)
Figure 2 Survival according to the degree of frailty and end- of- life trajectory: (A) cancer, (B) organ failure, (C) dementia and (D) 
multimorbidity.
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<0.8, similar to previous studies showing that the theo-
retical maximum score is 0.7. According to these studies, 
the accumulation of two- thirds of all possible deficits 
(Frailty index score >0.7) results in death due to the 
person’s inability to overcome more deficits, a phenom-
enon defined as system failure.33 34 Likewise, similar to 
previous studies in other populations, the mortality rate 
at 1–2 years in our cohort was nearly 100% for the EOLp 
with frailty index score >0.5.34 35
Furthermore, we provide evidence showing that the 
degree of frailty significantly influenced survival irre-
spective of the advanced illness and end- of- life trajec-
tory. In spite of this general influence, the survival curves 
according to the frailty degree followed different patterns 
for the four end- of- life trajectories, enabling the descrip-
tion of different frailty or deficit accumulation end- of- 
life trajectories according to the main disease, specially 
in the absence of advanced frailty. As the frailty degree 
increased, differences between trajectories decreased, 
resulting in a trend towards a compression of survival 
curves in advanced frailty situations where mortality 
is very high irrespective of the main advanced illness 
and end- of- life trajectory. Thus, in EOLp with cancer, 
mortality rates were high regardless of the frailty degree 
(moderate or advanced), leading to the hypothesis, 
similar to recent studies, that patients with cancer have 
a catastrophic accumulation of deficits.36 In contrast, 
EOLp with dementia showed different mortality rates 
according to their frailty degree and died progressively, 
likely due to the natural history of the disease, suggesting 
a slower accumulation of deficits. People with multimor-
bidity and advanced frailty shows a survival profile similar 
to people with cancer, while those with moderate frailty 
have a survival rate more similar to people with dementia. 
Finally, persons with an organ disease would accumulate 
deficits in episodes, even though prospective studies 
with serial frailty indexes would be required to test this 
hypothesis.
In this regard, similar to recent studies describing 
different trajectories according to the evolution of the 
social, spiritual or psychological situation of EOLp,3 
prospective studies following the degree of frailty 
using electronic frailty indexes have described three 
different trajectories (ie, rapidly rising frailty, moderately 
increasing frailty and stable frailty).36 Even though more 
studies would be required to describe different end- of- life 
frailty trajectories, the fact that each end- of- life trajectory 
resulted in different mortality curves supports a dynamic 
view of EOLp.
The traditional association of frailty to the ‘third end- of- 
life trajectory’ (ie, dementia)13 14 has probably been influ-
enced by the lack of specific prognostic instruments for 
persons in this trajectory, unlike those in the cancer37 38 
or organ disease39 40 trajectories. Our results regarding 
the high prevalence of frailty in all end- of- life trajecto-
ries support the validity of the concept that frailty may be 
present in all trajectories beyond the dementia trajectory. 
In addition to expanding the concept of frailty, our study 
underscores the need to consider a further development 
of the end- of- life trajectories. Of the 260 people who were 
identified as people in end- of- life situation, 24.6% did not 
have severity criteria for a single disease, although all of 
them had at least two chronic conditions. The identifi-
cation of this cluster of people with advanced frailty and 
multimorbidity can help provide them early palliative 
care, and the benefits derived from it.41 42
Frailty indices based on a Comprehensive Geriatric 
Assessment, such as the Frail- VIG index, may help profes-
sionals address one of the current challenges in palliative 
care18 19 43: the identification, assessment and management of 
Figure 3 Survival probability of end- of- life people in the different illness trajectories according to Frail- VIG index value: Frail- 
VIG index 0.44 (15th percentile) (A), Frail- VIG index 0.56 (median) (B) and Frail- VIG index 0.68 (90th percentile) (C).
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older people (ie, aged >80 years) with palliative care needs.20 44 
First, assessment and quantification of frailty degree, which is 
suitable to synthesise the results of a multidimensional evalu-
ation, can be useful to validate the identification of people in 
an end- of- life situation12; second, due to its ability to discrimi-
nate between different degrees of severity, frailty indexes can 
be very useful to healthcare professionals for the situational 
diagnosis of the first and second end- of- life transition,6 12 and 
monitorisation of EOLp evolution45 46; and finally, quantifica-
tion of frailty would enable palliative care customisation47 48 
and engage people, caregivers and healthcare professionals 
in sharing decision- making and advance care planning.
The results of this study should be interpreted in the 
context of some limitations, particularly regarding the gener-
alisability of the results. First, the recruitment strategy based 
on an AGU solely enriched our study sample with older 
patients, likely precluding the applicability of these study 
results to younger patients. Second, the analysis of EOLp 
frailty across the various end- of- life trajectory categories 
importantly reduced the number of patients in each group, 
thus limiting the statistical power of these analyses. However, 
despite the reduced number of patients in some groups, our 
analysis yielded statistically significant results. In spite of its 
limitations, to our knowledge, this study is the first to evaluate 
the degree of frailty using a frailty index in very old patients 
identified as EOLp. Frailty was evaluated in a cohort of geri-
atric patients, including EOLp and non- EOLp, and the data 
for this study were collected during routine geriatric assess-
ment, as opposed to previous studies that used electronic 
health record data to evaluate the degree of frailty.49 More-
over, the single computer information system of Catalonia 
(HC3) that collects the medical records and mortality status 
of all patients reported by all health providers prevented 
loss of patients up to follow- up.32 Consequently, the lack of 
missing data due to the HC3 system, along with the use of 
standard and validated tools to identify EOLp (NECPAL) and 
to measure frailty (Frail- VIG index), increased the accuracy 
of the results obtained from this study. The early identifica-
tion of people needing palliative care and the more accurate 
definition of the various end- of- life trajectories opened the 
door to a novel perspective of palliative care.50 In this regard, 
the use of frailty as an overarching concept in the assessment 
of all people in an end- of- life situation—at least of those with 
a multimorbid profile—might contribute to go one step 
further in this novel approach to palliative care.
CONCLUSIONS
Our results showed that all EOLp were frail (mostly with 
advanced frailty) irrespective of the end- of- life trajectory. 
Their degree of frailty, measured using the Frail- VIG index, 
influenced mortality. This indicates a close relationship 
between frailty, end- of- life status and mortality for all people 
who die. Measuring frailty using a frailty index could be 
useful in routine practice for healthcare professionals to 
understand the heterogeneous nature of people needing 
palliative care and tailor their care to the patient’s needs. 
The survival pattern of people with multimorbidity could 
support the description of a composite illness trajectory for 
this patient group.
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